Compare EXP & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXP | GPCR |
|---|---|---|
| Founded | 1963 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.3B |
| IPO Year | 1994 | 2023 |
| Metric | EXP | GPCR |
|---|---|---|
| Price | $173.11 | $48.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $226.44 | $103.36 |
| AVG Volume (30 Days) | 400.7K | ★ 829.0K |
| Earning Date | 01-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 1.18 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | ★ $495,023,000.00 | N/A |
| Revenue This Year | $1.84 | N/A |
| Revenue Next Year | $1.69 | N/A |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $175.59 | $13.24 |
| 52 Week High | $243.64 | $94.90 |
| Indicator | EXP | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 21.01 | 24.82 |
| Support Level | N/A | $18.36 |
| Resistance Level | $239.71 | $93.91 |
| Average True Range (ATR) | 5.68 | 3.50 |
| MACD | -2.66 | -0.60 |
| Stochastic Oscillator | 2.54 | 3.01 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.